Xi Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xi Qiu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Yang Xu
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 shared publications - Boxiao Chen
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 shared publications - Dijia Xin
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 shared publications - Huawei Jiang
Department of Hematology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China
12 shared publications - Jiandong Yu
Carbiogene Therapeutics Ltd., Hangzhou, China
12 shared publications - Jiangao Zhu
Carbiogene Therapeutics Ltd., Hangzhou, China
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Figure S1. A, control CAR (HBsAg CAR T), BCMA CAR and BCMA CAR-CD27 constructs were transduced into T cells, and CAR expression was detected by protein L assay. B, mock T, BCMA CAR and BCMA CAR-CD27 T cells were stained with anti-human CD27 antibodies. C, mock T and BCMA CAR-CD27 T cells were stained with fluorescence dye-labeled recombinant protein L and BCMA (rp), respectively. D, flow cytometry was used for detection of BCMA and CD70 on the cell surface of multiple cell lines. E, cell coculture was set-up as described in materials and methods. At Day 1 and 2 after coculture, supernatants were harvested for IFNγ measurement by ELISA. F, the transduced or non-transduced T cells were co-cultured with medium in the presence of anti-human CD107a for 1h, monensin was then added; and after 3h, cells were stained for CD3/CD4/CD8 antibodies and recombinant BCMA protein, and detected by flow cytometry. G and H, on day 15 after transduction, CAR-T cells were harvested and stained with CD4/CD8/ki67 antibodies and recombinant BCMA protein, and analyzed using flow cytometry (E); the percentage of Ki76+ cells in CD4+ and CD8+ CAR T cells were shown (F). * P<0.05.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Figure S1. A, control CAR (HBsAg CAR T), BCMA CAR and BCMA CAR-CD27 constructs were transduced into T cells, and CAR expression was detected by protein L assay. B, mock T, BCMA CAR and BCMA CAR-CD27 T cells were stained with anti-human CD27 antibodies. C, mock T and BCMA CAR-CD27 T cells were stained with fluorescence dye-labeled recombinant protein L and BCMA (rp), respectively. D, flow cytometry was used for detection of BCMA and CD70 on the cell surface of multiple cell lines. E, cell coculture was set-up as described in materials and methods. At Day 1 and 2 after coculture, supernatants were harvested for IFNγ measurement by ELISA. F, the transduced or non-transduced T cells were co-cultured with medium in the presence of anti-human CD107a for 1h, monensin was then added; and after 3h, cells were stained for CD3/CD4/CD8 antibodies and recombinant BCMA protein, and detected by flow cytometry. G and H, on day 15 after transduction, CAR-T cells were harvested and stained with CD4/CD8/ki67 antibodies and recombinant BCMA protein, and analyzed using flow cytometry (E); the percentage of Ki76+ cells in CD4+ and CD8+ CAR T cells were shown (F). * P<0.05.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term responses has yet to be established. We investigated the feasibility of CBG-002, a CD27-armored BCMA CAR T-cell therapy, to improve clinical efficacy in patients with RRMM. We present preclinical data showing the activity of CBG-002 against myeloma and results from a phase I clinical trial (NCT04706936) evaluating its safety and efficacy in patients with RRMM. The primary endpoint was safety, as assessed by grade 3 or 4 adverse events (AE). Key secondary endpoints were overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 11 patients were enrolled and received CBG-002 therapy. Nine patients developed grade 1 or 2 cytokine release syndrome (CRS), whereas no patients experienced grade 3 or higher CRS or immune effector cell–associated neurotoxicity syndrome. Other grade 3 or higher AEs included neutropenia (72.7%), thrombocytopenia (45.5%), and anemia (36.4%). At a median follow-up of 16.7 months, the ORR was 81.8%, including a stringent complete response/complete response rate of 45.5%, very good partial response rate of 18.2%, and partial response rate of 18.2%, with a median DOR of 8.9 (range 1.8–21.9) months. The median OS was not reached, and the median PFS was 8.5 (2.7–22.9) months. In this phase I study, CBG-002, a CD27-armored BCMA CAR T-cell therapy, demonstrated safety and clinical efficacy in patients with RRMM.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term responses has yet to be established. We investigated the feasibility of CBG-002, a CD27-armored BCMA CAR T-cell therapy, to improve clinical efficacy in patients with RRMM. We present preclinical data showing the activity of CBG-002 against myeloma and results from a phase I clinical trial (NCT04706936) evaluating its safety and efficacy in patients with RRMM. The primary endpoint was safety, as assessed by grade 3 or 4 adverse events (AE). Key secondary endpoints were overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 11 patients were enrolled and received CBG-002 therapy. Nine patients developed grade 1 or 2 cytokine release syndrome (CRS), whereas no patients experienced grade 3 or higher CRS or immune effector cell–associated neurotoxicity syndrome. Other grade 3 or higher AEs included neutropenia (72.7%), thrombocytopenia (45.5%), and anemia (36.4%). At a median follow-up of 16.7 months, the ORR was 81.8%, including a stringent complete response/complete response rate of 45.5%, very good partial response rate of 18.2%, and partial response rate of 18.2%, with a median DOR of 8.9 (range 1.8–21.9) months. The median OS was not reached, and the median PFS was 8.5 (2.7–22.9) months. In this phase I study, CBG-002, a CD27-armored BCMA CAR T-cell therapy, demonstrated safety and clinical efficacy in patients with RRMM.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Representativeness of Study Participants
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Representativeness of Study Participants